Peri-operative atezolizumab in early-stage triple-negative breast cancer
Final results from the IMpassion031 trial confirm that adding atezolizumab to neoadjuvant chemotherapy significantly improved clinical outcomes and cleared ctDNA at surgery
Day: August 27, 2025